Allergy Therapeutics focuses on innovative immunotherapy treatments aimed at alleviating the burden of allergies, which can significantly impact quality of life. The company specializes in both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), which are designed to address the underlying causes of allergic reactions rather than merely managing symptoms. SCIT involves a series of controlled injections to build tolerance to specific allergens, while SLIT allows patients to self-administer treatment at home using drops or tablets placed under the tongue. This approach not only enhances patient convenience but also aims to provide long-term relief from allergy symptoms.

In addition to their immunotherapy products, Allergy Therapeutics has developed advanced adjuvant technologies that enhance the efficacy of allergy treatments and have potential applications in cancer and infectious disease research. Their adjuvant systems are designed to improve immune responses, making therapies act more quickly and effectively. The company is actively engaged in partnerships to leverage these patented technologies for the development of vaccines and immunotherapies, further solidifying its commitment to addressing global healthcare challenges through innovation and expertise in the field of immunology.

United Kingdom

Allergy Therapeutics is a visionary immunology business with specialist experience in the research and development of allergy treatments. We have a well-established commercial presence in Europe and are focused on the US market.

We specialise in the diagnosis and treatment of allergy. We mainly sell our products in European countries and our pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, as well as a peanut allergy vaccine in pre-clinical development.

Adjuvant systems to boost performance of vaccines outside of allergy are also under evaluation.

Allergy Therapeutics

Company Details